The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Early data with the RIPTAC HLD-0915 look competitive.
